Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Change in Account Payables (2023 - 2025)

Historic Change in Account Payables for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $1.9 million.

  • Immunome's Change in Account Payables rose 18875.71% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 66335.7%. This contributed to the annual value of $9.5 million for FY2024, which is 166677.63% up from last year.
  • According to the latest figures from Q3 2025, Immunome's Change in Account Payables is $1.9 million, which was up 18875.71% from -$4.9 million recorded in Q2 2025.
  • Immunome's 5-year Change in Account Payables high stood at $9.3 million for Q4 2024, and its period low was -$4.9 million during Q2 2025.
  • For the 3-year period, Immunome's Change in Account Payables averaged around $184636.4, with its median value being -$32000.0 (2024).
  • As far as peak fluctuations go, Immunome's Change in Account Payables skyrocketed by 146524.3% in 2024, and later tumbled by 1536250.0% in 2025.
  • Immunome's Change in Account Payables (Quarter) stood at -$679000.0 in 2023, then surged by 1465.24% to $9.3 million in 2024, then plummeted by 79.82% to $1.9 million in 2025.
  • Its Change in Account Payables was $1.9 million in Q3 2025, compared to -$4.9 million in Q2 2025 and -$3.8 million in Q1 2025.